Avelumab and Merkel Cell Carcinoma: A Clinical Evidence Review
From General Health Information to Focused Exposure Inquiry
General health and science information has long served as a foundation for public understanding of disease prevention and treatment. Within this broad context, discussions of cancer therapies and their mechanisms have typically focused on clinical efficacy and patient outcomes. As the field evolves, attention increasingly turns to the specific circumstances under which therapeutic agents are introduced into the body, including potential unintended consequences of exposure. This shift in perspective is particularly relevant when examining biologic therapies such as Avelumab, a monoclonal antibody used in oncology. While the legacy framework emphasizes general health benefits and risk-benefit profiles, a more targeted inquiry now considers whether occupational or environmental exposure to such agents could contribute to disease development. The transition from a general health context to a focused concern about Avelumab exposure and Merkel cell carcinoma risk requires careful delineation of exposure pathways, whether through clinical administration, manufacturing processes, or other routes. This pivot does not presuppose causation but rather establishes a framework for systematic review of available clinical evidence. By moving from broad health principles to specific exposure scenarios, the analysis can better address questions of potential risk without invoking mechanistic claims, maintaining a neutral academic stance throughout the evaluation.
Clinical Profile of Avelumab and Its Role in Merkel Cell Carcinoma
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the USA, EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/29799096/). This approval marked avelumab as the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a highly aggressive skin cancer with neuroendocrine differentiation, associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).
Adverse Events and Treatment Resistance with Avelumab
Avelumab is known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case describes hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab; the hypercalcaemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates the potential for avelumab to trigger immune-mediated complications beyond typical irAEs, including reactivation of underlying granulomatous diseases. For patients who become refractory to avelumab, treatment options are limited. A retrospective study of five patients at three German academic sites found that three out of five patients with avelumab-refractory metastatic MCC responded to combined ipilimumab plus nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study from the prospective skin cancer registry ADOREG similarly reported that ipilimumab plus nivolumab can be effective in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). These findings highlight the need for alternative therapies after avelumab failure.
Causation Considerations: Avelumab as Treatment, Not Cause
Regarding causation considerations, the timeline between avelumab exposure and documented harm is relevant. In the case of hypercalcaemia due to sarcoidosis reactivation, the adverse event occurred during treatment with avelumab, and resolution was achieved with corticosteroids while continuing avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). For avelumab-refractory disease, progression is documented during or after avelumab therapy, with subsequent response to alternative checkpoint inhibition (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/36450381/). The mechanistic pathway linking avelumab to MCC is through PD-L1 inhibition, which enhances anti-tumor immune responses but can also lead to immune-related adverse events (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, avelumab is not a cause of MCC; rather, it is a treatment for MCC. The evidence does not support a causal relationship between avelumab and the development of MCC. Instead, avelumab is used to treat existing MCC, and its adverse effects are related to immune activation. Risk considerations include the adequacy of warnings regarding avelumab and MCC. The prescribing information for avelumab includes warnings about immune-mediated adverse events, but the specific risk of sarcoidosis reactivation may not be prominently highlighted. For affected patients, the risk of progression on avelumab is significant, with approximately 50% of patients not responding or progressing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The timeline between exposure and documented harm varies: immune-related adverse events can occur at any time during treatment, while refractory disease is typically identified after several cycles of therapy. Patients and clinicians should be aware of the potential for immune-related adverse events and the need for alternative therapies if avelumab fails. In summary, avelumab is an effective treatment for metastatic MCC, but it carries risks of immune-related adverse events and a substantial rate of treatment failure. The evidence does not indicate that avelumab causes MCC; rather, it is a therapeutic agent for the disease. Causation considerations focus on adverse events and treatment resistance, not on avelumab as a trigger for MCC.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
Does avelumab cause Merkel cell carcinoma?
No, avelumab is a treatment for Merkel cell carcinoma, not a cause. It is an immune checkpoint inhibitor used to treat existing MCC. The evidence does not support a causal relationship between avelumab and the development of MCC.
What are the risks of avelumab therapy?
Avelumab can cause immune-related adverse events such as hypercalcaemia from sarcoidosis reactivation, and approximately 50% of patients may not respond or progress on therapy. Alternative treatments like ipilimumab plus nivolumab may be effective in avelumab-refractory cases.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Free and confidential. No obligation — an initial records screening only.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.